Pharmacyclics LLC v. Alvogen, Inc.

  1. November 15, 2022

    Fed. Circ. Allows AbbVie, J&J To Fend Off Imbruvica Generic

    The Federal Circuit on Tuesday handed a win to Abbvie's Pharmacyclics and Johnson & Johnson's Janssen Biotech by saying a generic version of their blockbuster cancer drug Imbruvica infringes their patents, and that those patents aren't invalid.

  2. October 07, 2022

    Alvogen Continues IP Fight Over Cancer Drug Imbruvica

    In a rematch over the leukemia medication Imbruvica, AbbVie's Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech urged the Federal Circuit Friday to uphold a lower court ruling that their four patents related to the blockbuster drug are valid.

  3. September 29, 2022

    IP Forecast: Philip Morris Looks To Snuff Out ITC Ban

    Two of the largest tobacco companies in the world head to the Federal Circuit to fight over a ban R.J. Reynolds won at the U.S. International Trade Commission that blocked Philip Morris from importing IQOS-branded heated tobacco products into the U.S. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.